James E Flynn has bought stock on 32 days since Jan 2016
* Director by Deputization, 10% at Larimar Therapeutics, Inc., and 39 other companies
SEC CIK 0001352546 · Filings on SEC.gov ↗
James E Flynn's record
3 months after each buy, from the first price a copier could get.
9 buys since 2016 with 3 months of prices.
Companies
- LRMR Larimar Therapeutics, Inc.* Director by Deputization, 10%
- NUVL Nuvalent, Inc.Director by Deputization, 10%
- SPRY ARS Pharmaceuticals, Inc.10% owner
- BCAX Bicara Therapeutics Inc.Possible Members of 10% Group, 10%
- AHCO AdaptHealth Corp.*Possible Member of 10% Group, 10%
- ONCR Oncorus, Inc.Possible Member of 10% Group, 10%
- MIRM Mirum Pharmaceuticals, Inc.* Possible Member of 10% Group, 10%
- PEPG PepGen Inc.Possible Member of 10% Group, 10%
- XLO Xilio Therapeutics, Inc.Possible Member of 10% Group, 10%
- OMIC Singular Genomics Systems, Inc.*Possible Member of 10% Group, 10%
- HOWL Werewolf Therapeutics, Inc.Possible Member of 10% Group, 10%
- EWTX Edgewise Therapeutics, Inc.Possible Member of 10% Group, 10%
- TERN Terns Pharmaceuticals, Inc.Possible Member of 10% Group, 10%
- LUMO Lumos Pharma, Inc.*Possible Member of 10% Group, 10%
- GRAY Graybug Vision, Inc.*Possible Member of 10% Group, 10%
- AFIB Acutus Medical, Inc.Director by Deputization, 10%
- RVMD Revolution Medicines, Inc.Possible Member of 10% Group, 10%
- SDGR Schrödinger, Inc.Possible Member of 10% Group, 10%
- BDTX Black Diamond Therapeutics, Inc.Possible Member of 10% Group, 10%
- FIXX Leverage Shares 2X Long FIX Daily ETFPossible Member of 10% Group, 10%
- CABA Cabaletta Bio, Inc.Possible Member of 10% Group, 10%
- FREQ Frequency Therapeutics, Inc.Possible Member of 10% Group, 10%
- ACRS Aclaris Therapeutics, Inc.10% owner
- SWAV Shockwave Medical, Inc.Possible Member of 10% Group, 10%
- ARVN Arvinas, Inc.Possible Member of a 10% Group, 10%
- CNST Constellation Pharmaceuticals IncPossible Member of 10% Group, 10%
- AVDL Avadel Pharmaceuticals Plc*Possible member of 10% group, 10%
- MNK Mallinckrodt Plc*Possible member of 10% group, 10%
- PRTO RCN Pareto Strategic Allocation ETF*Director by Deputization
- RYTM Rhythm Pharmaceuticals, Inc.Possible Member of 10% Group, 10%
- REPH Recro Pharma, Inc.Possible Member of 10% Group, 10%
- EHTH eHealth, Inc.Possible Members of 10% Group, 10%
- CASM Cas Medical Systems IncPossible Member of 10% Group, 10%
- IVTY Invuity, Inc.Possible Member of 10% Group, 10%
- VNDA Vanda Pharmaceuticals Inc.Possible Member of 10% Group, 10%
- ZFGN Zafgen, Inc.Possible Member of 10% Group, 10%
- AXGN Axogen, Inc.Possible Member of 10% Group, 10%
- SYRS Syros Pharmaceuticals, Inc.Possible Members of 10% Group, 10%
- EDIT Editas Medicine, Inc.Possible Member of 10% Group, 10%
- XNPT Xenoport IncPossible Member of 10% Group, 10%
Every filing
69 filings since Jan 2016, newest first
Ehealth, Inc.
Possible Members of 10% Group, 10%
Ehealth, Inc.
Possible Members of 10% Group, 10%
Cas Medical Systems Inc
Possible Member of 10% Group, 10%
Cas Medical Systems Inc
Possible Member of 10% Group, 10%
Invuity, Inc.
Possible Member of 10% Group, 10%
Vanda Pharmaceuticals Inc.
Possible Member of 10% Group, 10%
Vanda Pharmaceuticals Inc.
Possible Member of 10% Group, 10%
Zafgen, Inc.
Possible Member of 10% Group, 10%
Axogen, Inc.
Possible Member of 10% Group, 10%
Axogen, Inc.
Possible Member of 10% Group, 10%
Syros Pharmaceuticals, Inc.
Possible Members of 10% Group, 10%
Ehealth, Inc.
Possible Members of 10% Group, 10%
Ehealth, Inc.
Possible Members of 10% Group, 10%
Ehealth, Inc.
Possible Members of 10% Group, 10%
Ehealth, Inc.
Possible Members of 10% Group, 10%
Ehealth, Inc.
Possible Members of 10% Group, 10%
Zafgen, Inc.
Possible Member of 10% Group, 10%
Editas Medicine, Inc.
Possible Member of 10% Group, 10%
Xenoport Inc
Possible Member of 10% Group, 10%
About James E Flynn
James E. Flynn is the Managing Partner of Deerfield Management, a leading healthcare-focused investment firm, where he joined in 2000 and assumed leadership in 2005.( Under his direction, Deerfield has expanded into healthcare information via the Deerfield Institute, venture investments, Deerfield Discovery and Development, LLC, the Deerfield Foundation, and a New York City innovation center.( Previously, he was a top-ranked analyst at Furman Selz (ING Barings), Vice President of Corporate Development at Alpharma Inc., and a senior analyst at Kidder, Peabody & Co.(
Flynn serves as Director by Deputization, 10% Owner at Nuvalent, Inc. (NUVL), holding approximately 17 million shares valued over $1.4 billion as of mid-2025, reflecting Deerfield's significant stake.( He holds a BS in Cellular and Molecular Biology and Economics from the University of Michigan and an MS in Biotechnology from Johns Hopkins University, and serves on boards including Mount Sinai Health System and as Chairman of the New York Academy of Medicine.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.